|
|
Vaccine Detail
|
HSP65-HER2 fusion peptide |
| Vaccine Information |
- Vaccine Name: HSP65-HER2 fusion peptide
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007614
- Type: Peptide based vaccine
- Status: Research
-
Adjuvant:
HSP65-HER2 (Wang et al., 2013)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: loading of iDCs with HSP65-HER2 induced the expression of CD86 in vitro, HSP65-HER2 immunization significantly reduced the percentages of HER2(+) B16 cells in xenografted tumors(Finocchiaro and Glikin, 2012)
|
| References |
Finocchiaro and Glikin, 2012: Finocchiaro LM, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer gene therapy. 2012; 19(12); 852-861. [PubMed: 23059870].
Wang et al., 2013: Wang J, Wang X, Chen Y, Wan M, Xiang Z, Wu X, Wei H, Wang L, Zhang P, Wang L, Yu Y. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(1); 193-201. [PubMed: 23055194].
|
|
